Table 2: Prophylactics.
Name of the drug |
Mode of action |
Current status of Clinical trial |
References |
Hydroxychloroquine |
1. Inhibition of virus fusion caused by elevated endosomal pH. 2. Impairment of terminal glycosylation of ACE2. |
1. Controversial results. 2. Removed from clinical trial. |
[99] [100] |
Azithromycin |
1. Increased endosomal pH inhibits viral fusion. 2. Also an immunomodulator. |
1. Moderate efficacy. 2. Controversial results. |
[101] [102] |
Arbidol hydrochloride |
Inhibits viral entry by inhibition of endocytosis or membrane fusion. It also inhibits viral RNA synthesis. |
Not yet approved by FDA. |
[103] [104] |